ABCL Biotech Investment Thesis

Author: 10Baggers (@devang_shah)
Source: X/Twitter
Date: 2026-05-13

Original Content

Stage 1 math. What a clean Phase 2 hit in Q3 is actually worth:

• Phase 3 Odds of success: 55-65%
• Risk-adj peak sales (60% of half TAM): $3B × 60% = $1.8B
• Peak multiple 4.5x = $8.1B
• PV @ 12% over ~6yrs ≈ $4.1B
• ABCL635 alone: ~$4-4.5B EV (~3X from current price)

Other buckets:

• Cash + gov't funding: ~$0.65B
• Royalty book (bam residual + others): ~$0.3-0.4B
• Pipeline (575/688/386 + 20 discovery): ~$0.3-0.5B
• Platform (Trianni/Celium): ~$0.3-0.5B
• Non-635 total: ~$1.6-2.1B

Stage 1 EV: ~$5.6-6.6B ÷ 305M shares = ~$18-22/share = 3.5-4x from here. The biggest single re-rating on the entire ABCL635 path is right here at the Q3 readout. Phase 3 approval.

Summary

Bullish thesis on $ABCL (AbCellera Biologics) focused on ABCL635 Phase 3 readout in Q3. Risk-adjusted valuation of $18-22/share (3.5-4x upside from ~$5-6/current). Total enterprise value estimated at $5.6-6.6B across drug pipeline, cash, royalties, and platform technology (Trianni/Celium). Downside: $2.5-3 (worst case), upside: $20+ by EOY on positive readout.

Metrics

• Likes: 22
• Reposts: 2
• Comments: 3
• Views: 2.3K

Relevance to FACorreia Projects

Low direct relevance — biotech deep-dive. Useful reference if $ABCL is or becomes part of a tracked portfolio position. No application impact.